

CLARIO.

Clario's Precision Motion solutions are reinventing mobility measurement in clinical trials with the Opal V2C@ wearable sensor system for capturing digital gait, postural sway, and physical activity endpoints.

Clario's patented, synchronized Opal sensors capture DiMe's standardized measures of physical activity, ambulation, and balance to help reduce the sample size and duration of clinical trials.


— Fay Horak, PhD

Chief Scientist, Clario – Precision Motion

The opportunity



Digital mobility measures (e.g., gait, postural sway, and physical activity) reflect meaningful aspects of a patient's overall health and quality of life and improve the efficiency and accessibility of clinical trials. Opal V2C@ sensors capture precise aspects of mobility with greater sensitivity to progression than clinical scales.



The impact



DiMe's standardized approach benefits sponsors looking to incorporate digital measures of gait, postural sway, and physical activity.

- ✓ Identifies measures where there is evidence to support use in the patient population
- ✓ Informs strategy for selecting digital health technologies and endpoints
- ✓ Offers better alignment across sponsors, vendors, and regulators

The resources



[DATAcc by DiMe's core measures of physical activity](#) are selected based on the maturity of technology, their applicability as endpoints in clinical trials, and overall readiness for adoption. In addition to the core measures, Clario's team embraces DATAcc's [V3+ Framework](#) as a powerful tool for making informed, data-driven decisions when selecting digital health technologies tailored to clinical trial needs.

